Downloads provided by UsageCounts
In an effort to develop clinical compounds for Diffused Intrinsic Pontine Glioma (DIPG) treatment, new analogues of ACVR1/ALK2 inhibitors are continuously synthesised by Ontario Institute for Cancer Research (OICR) and Charles River Laboratories (CRL). I will provide prompt feedback of the cellular assay results to guide their design of new compounds. The blog post for this page can be found on the SGC opennotebook site: https://openlabnotebooks.org/determining-the-nanobret-al2k-ic50-values-of-24-new-acvr1-alk2-inhibitors/
Inhibitor, NanoBRET, ACVR1, ALK2
Inhibitor, NanoBRET, ACVR1, ALK2
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
| views | 5 | |
| downloads | 1 |

Views provided by UsageCounts
Downloads provided by UsageCounts